Daiichi Sankyo Company, Limited4568.T
Oncology40 cited findings · profile updated 2026-08-20
About Daiichi Sankyo Company, Limited
4568.T is an oncology research site with regulatory documents detailing findings for Enhertu. In the DESTINY-Breast03 trial, Enhertu was associated with a 76% incidence of all-grade nausea and a 7% incidence of Grades 3-4 nausea. Other notable adverse events in DESTINY-Breast03 included decreased hemoglobin (64% all grades, 7% Grades 3-4) and decreased neutrophil count (70% all grades, 18% Grades 3-4). In the DESTINY-Breast02 trial, all-grade fatigue was observed in 62% of patients, with 9% experiencing Grades 3-4 fatigue. Diarrhea was reported in 27% of patients (all grades) and 2.7% (Grades 3-4) in DESTINY-Breast02. For Study U204 (DESTINY-Lung01) in HER2 mutant NSCLC, Grade ≥3 TEAEs were 69%, and Grade ≥3 ILD or pneumonitis occurred in 6 patients.
Compiled from the cited findings below — figures are as stated in each company's published technical reports and filings.
Key figures — cited
| Nausea (all grades) | 76 % | DAIICHI SANKYO — Enhertu FDA Review (NDA/BLA 761139, 2025), p.22 |
| Decreased hemoglobin (all grades) | 64 % | DAIICHI SANKYO — Enhertu FDA Review (NDA/BLA 761139, 2025), p.24 |
| Fatigue (all grades) | 62 % | DAIICHI SANKYO — Enhertu FDA Review (NDA/BLA 761139, 2025), p.25 |
| Increased aspartate aminotransferase (all grades) | 67 % | DAIICHI SANKYO — Enhertu FDA Review (NDA/BLA 761139, 2025), p.24 |
| Grade ≥3 TEAEs (Study U204 HER2 mutant NSCLC) | 69% | DAIICHI SANKYO — Enhertu FDA Review (NDA/BLA 761139, 2023), p.335 |
| Decreased neutrophil count (all grades) | 70 % | DAIICHI SANKYO — Enhertu FDA Review (NDA/BLA 761139, 2025), p.24 |
Key projects
- Enhertu (HER2 mutant NSCLC)
In Study U204 (DESTINY-Lung01), Grade ≥3 TEAEs were 69%.
- Enhertu (breast cancer)
In the DESTINY-Breast03 trial, all-grade nausea was 76%.
- Enhertu (breast cancer)
In the DESTINY-Breast02 trial, all-grade fatigue was 62%.
Every figure cites its source document. Prices refresh daily, not live. Informational only — not investment advice. Explore the Oncology research library →